caa a22 4500 445338962 CHVBK 20180317142805.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-1800-6 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1800-6 Adjuvant Chemolipiodolization Reduces Early Recurrence Derived from Intrahepatic Metastasis of Hepatocellular Carcinoma After Hepatectomy [Elektronische Daten] [Masaki Ueno, Kazuhisa Uchiyama, Satoru Ozawa, Shinya Hayami, Yoshinobu Shigekawa, Masaji Tani, Hiroki Yamaue] Background: The recurrence of hepatocellular carcinoma is still high even after surgery. Two general recurrence patterns occur: intrahepatic metastasis (IM) and multicentric carcinogenesis (MC). The aim of this study was to investigate the effectiveness of adjuvant chemolipiodolization for reducing IM or MC recurrences after surgery. Methods: A retrospective case-control study was carried out. From April 2005, adjuvant chemolipiodolization was performed in 63 initial hepatocellular carcinoma patients 3months after surgery. Sixty-four patients who underwent surgery between April 2001 and March 2005 were analyzed as the control group. Recurrence-free and overall survival as well as prognostic factors were analyzed univariately and multivariately. Results: The 2-year recurrence-free survival was 57% in the chemolipiodolization group and 37% in the control group (P=0.02). However, there was no significant difference at 5years after surgery (P=0.09). The 5-year overall survival rates in the chemolipiodolization and the control groups were 82.4 and 55.7%, respectively (P=0.04). Cox proportional multivariate analysis revealed that adjuvant chemolipiodolization was an independent favorable prognostic factor for 2-year recurrence-free survival, and the odds ratio [95% confidential interval] was 0.55 [0.34-0.90] (P=0.02). However, adjuvant chemolipiodolization was not an independent favorable prognostic factor for 5-year overall survival. Conclusions: Adjuvant chemolipiodolization can reduce the risk of early recurrences, which would be mainly IM derived. However, chemolipiodolization did not reduce late phase recurrences after surgery, which would be mainly MC derived. To prevent late phase recurrences, another novel strategy would be needed. Society of Surgical Oncology, 2011 Ueno Masaki Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Uchiyama Kazuhisa Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Ozawa Satoru Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Hayami Shinya Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Shigekawa Yoshinobu Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Tani Masaji Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Yamaue Hiroki Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3624-3631 1068-9265 18:13<3624 2011 18 10434 https://doi.org/10.1245/s10434-011-1800-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1800-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ueno Masaki Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Uchiyama Kazuhisa Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Ozawa Satoru Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Hayami Shinya Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Shigekawa Yoshinobu Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Tani Masaji Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 700 1- Yamaue Hiroki Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama City, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3624-3631 1068-9265 18:13<3624 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer